Phase III trial of VM202 in the patient with critical limb ischemia (CLI).

Trial Profile

Phase III trial of VM202 in the patient with critical limb ischemia (CLI).

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Peripheral arterial disorders; Peripheral ischaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2017 New trial record
    • 12 Nov 2017 According to a ViroMed media release, IND has been approved by the China Food and Drug Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top